NasdaqGS - Delayed Quote USD

PTC Therapeutics, Inc. (PTCT)

25.97 +0.65 (+2.57%)
At close: April 22 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
937,822.00
937,822.00
698,801.00
538,593.00
380,766.00
Cost of Revenue
65,486.00
65,486.00
44,678.00
32,328.00
18,942.00
Gross Profit
872,336.00
872,336.00
654,123.00
506,265.00
361,824.00
Operating Expense
1,221,738.00
1,221,738.00
1,094,048.00
881,208.00
759,699.00
Operating Income
-349,402.00
-349,402.00
-439,925.00
-374,943.00
-397,875.00
Net Non Operating Interest Income Expense
-129,180.00
-129,180.00
-90,871.00
-86,022.00
-56,352.00
Other Income Expense
-217,528.00
-217,528.00
-56,691.00
-57,375.00
51,295.00
Pretax Income
-696,110.00
-696,110.00
-587,487.00
-518,340.00
-402,932.00
Tax Provision
-69,506.00
-69,506.00
-28,470.00
5,561.00
35,228.00
Net Income Common Stockholders
-626,604.00
-626,604.00
-559,017.00
-523,901.00
-438,160.00
Diluted NI Available to Com Stockholders
-626,604.00
-626,604.00
-559,017.00
-523,901.00
-438,160.00
Basic EPS
-8.67
-8.37
-7.79
-7.43
-6.64
Diluted EPS
-8.67
-8.37
-7.79
-7.43
-6.64
Basic Average Shares
74,130.71
74,838.39
71,728.63
70,466.39
66,027.91
Diluted Average Shares
74,130.71
74,838.39
71,728.63
70,466.39
66,027.91
Total Operating Income as Reported
-439,502.00
-439,502.00
-447,409.00
-374,443.00
-431,768.00
Total Expenses
1,287,224.00
1,287,224.00
1,138,726.00
913,536.00
778,641.00
Net Income from Continuing & Discontinued Operation
-626,604.00
-626,604.00
-559,017.00
-523,901.00
-438,160.00
Normalized Income
-421,711.80
-421,711.80
-551,895.23
-524,266.00
-413,418.11
Interest Expense
129,180.00
129,180.00
90,871.00
86,022.00
56,352.00
Net Interest Income
-129,180.00
-129,180.00
-90,871.00
-86,022.00
-56,352.00
EBIT
-566,930.00
-566,930.00
-496,616.00
-432,318.00
-346,580.00
EBITDA
-330,340.00
-330,340.00
-367,780.00
-368,184.00
-303,090.00
Reconciled Cost of Revenue
51,531.00
51,531.00
32,396.00
22,945.00
12,344.00
Reconciled Depreciation
236,590.00
236,590.00
128,836.00
64,134.00
43,490.00
Net Income from Continuing Operation Net Minority Interest
-626,604.00
-626,604.00
-559,017.00
-523,901.00
-438,160.00
Total Unusual Items Excluding Goodwill
-227,658.00
-227,658.00
-7,484.00
500.00
-33,893.00
Total Unusual Items
-227,658.00
-227,658.00
-7,484.00
500.00
-33,893.00
Normalized EBITDA
-102,682.00
-102,682.00
-360,296.00
-368,684.00
-269,197.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-22,765.80
-22,765.80
-362.23
135.00
-9,151.11
12/31/2020 - 6/20/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AGIO Agios Pharmaceuticals, Inc.
30.21
+2.30%
 
MORF Morphic Holding, Inc.
28.50
+1.82%
 
PRTA Prothena Corporation plc
21.29
+0.61%
 
FOLD Amicus Therapeutics, Inc.
10.82
+1.98%
 
ENTA Enanta Pharmaceuticals, Inc.
13.44
+0.90%
 
PTGX Protagonist Therapeutics, Inc.
26.61
+3.90%
 
RGNX REGENXBIO Inc.
15.64
-0.32%
 
TVTX Travere Therapeutics, Inc.
5.85
+2.27%
 
KROS Keros Therapeutics, Inc.
55.78
-4.29%
 
MGTX MeiraGTx Holdings plc
5.02
-1.38%